In patients treated with ranibizumab during the core study , consecutive individualized ranibizumab treatment during the extension study led to an overall maintenance of BCVA and central retinal subfield thickness ( CRST ) observed at month 12 over the 2-year extension study ( +8.0 letters , -142.1 m [ prior ranibizumab ] and +6.7 letters , -145.9 m [ prior ranibizumab + laser ] from baseline at month 36 ) with a median of 6.0 injections ( mean , 6.8 injections ; prior ranibizumab ) and 4.0 ( mean , 6.0 injections ; prior ranibizumab + laser ) .